• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

	Semnur Pharmaceuticals, Inc. (DECA)
	Q1-CY2026	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014	Q1-CY2014
Balance Sheet Date		2025-Dec-31	2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31	2024-Sep-30	2024-Jun-30	2024-Mar-31	2023-Dec-31
Fiscal Period		Q4-FY2025	Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024	Q3-FY2024	Q2-FY2024	Q1-FY2024	Q4-FY2023
Total Revenue						50,000,000$			50,000,000$
QoQ%
YoY%
Cost Of Revenue						0$			0$
Gross Profit						50,000,000$			50,000,000$
Gross Margin						100.00%			100.00%
Operating Expenses		6,158,000$	152,594,000$	374,857$	246,600$	776,000$	1,298,000$	168,186$	50,368,252$	182,482$	505,895$	563,701$	1,921,748$
Operating Income		(6,158,000$)	(152,594,000$)	(374,857$)	(246,600$)	(776,000$)	(1,298,000$)	(168,186$)	(368,252$)	(182,482$)	(505,895$)	(563,701$)
Operating Margin						(1.55%)			(.74%)
Interest Income				18,080$	78,971$	86,722$	197,278$	640,157$	653,885$	753,537$	1,151,229$	1,025,859$	912,646$
Interest Expenses				28,345$	26,974$			23,059$	21,303$	100,000$
Income Before Tax		(6,158,000$)	(152,594,000$)	(999,000$)	(665,000$)	(167,306$)	(1,298,000$)	(1,110,000$)	(1,506,000$)	632,536$	630,586$	457,709$	(1,009,102$)
Tax Expenses
Net Income		(6,158,000$)	(152,594,000$)	(999,000$)	(665,000$)	(167,306$)	(1,298,000$)	(1,110,000$)	(1,506,000$)	632,536$	630,586$	457,709$	(1,009,102$)
Profit Margin						(.34%)			(3.01%)
TTM
Earnings to Minority
Earnings to Common Shareholders		(6,158,000$)	(152,594,000$)	(999,000$)	(665,000$)	(167,306$)	(1,298,000$)	(1,110,000$)	(1,506,000$)	632,536$	630,586$	457,709$	(1,009,102$)
QoQ%		95.96%	(15,174.68%)	(50.23%)	(297.48%)	87.11%	(16.94%)	26.30%	(338.09%)	.31%	37.77%	145.36%
YoY%		(3,580.68%)	(11,656.09%)	10.00%	55.84%	(126.45%)	(305.84%)	(342.51%)	(49.24%)
Earnings Per Share, Basic			(0.76$)				(0.01$)
Earnings Per Share, Diluted			(0.76$)				(0.01$)
Unlevered FCF Per Share, Basic			(0.01$)				(0.01$)
Unlevered FCF Per Share, Diluted			(0.01$)				(0.01$)
Average Shares, Basic			201,686,617				200,000,000
Average Shares, Diluted			201,686,617				200,000,000
EBIT		(6,158,000$)	(152,594,000$)	(970,655$)	(638,026$)	(167,306$)	(1,298,000$)	(1,086,941$)	(1,484,697$)	732,536$	630,586$	457,709$	(1,009,102$)
EBITDA		(6,158,000$)	(152,594,000$)	(970,655$)	(638,026$)	(167,306$)	(1,298,000$)	(1,086,941$)	(1,484,697$)	732,536$	630,586$	457,709$	(1,009,102$)

Copy Table ✓